Understanding the pharmacokinetics of each compound you use, whether GLP-1 or otherwise, is the foundation of effective and safe protocol management
In the Ozempic litigation, Science Day will provide valuable insights for all parties, offering a clearer picture of the upcoming legal process
Marx N, Federici M, Schtt K, et al
One obvious advantage of the small molecule agonists in the replacement of peptide GLP-1 analogues is that they could be administered orally, thus avoiding the discomfort of subcutaneous injections and increasing the compliance of patients
However, all these treatments are symptomatic and cannot prevent or reverse AD pathology ( Figure 1 ) ( Figure 1 Biological characteristics of GLP-1 In the 1980s, a new glucagon-like peptide, produced from proglucagon cleavage, was discovered to stimulate insulin secretion ( GLP-1, a 36-amino acid peptide, is produced in enteroendocrine L-cells of the distal small bowel and colon ( The effect of GLP-1 depends on blood glucose levels since it can only potentiate glucose-stimulated insulin secretion from islet beta cells in the hyperglycemic state rather than in the normal blood glucose state (98101)